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Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate frequency (200 kHz), which have 
been demonstrated to block cell division and interfere with organelle assembly. This novel treatment modality has shown prom-
ise in a variety of tumor types. It has been evaluated in randomized phase 3 trials in glioblastoma (GBM) and demonstrated to 
prolong progression-free survival (PFS) and overall survival (OS) when administered together with standard maintenance temo-
zolomide (TMZ) chemotherapy in patients with newly diagnosed GBM. TTFields are continuously delivered by 4 transducer arrays 
consisting each of 9 insulated electrodes that are placed on the patient’s shaved scalp and connected to a portable device. Here 
we summarize the preclinical data and mechanism of action, the available clinical data, and further outlook of this treatment 
modality in brain tumors and other cancer indications.
Preclinical Data and Mechanism of Action
Living cells consist of charged or polar molecules and ions and 
thus are responsive to electrical fields and currents. Electric 
activity of cells plays a key role in many essential biological 
processes including cell division. Cellular processes can be 
influenced by electric fields. The overall effect will depend 
upon the magnitude of the potential difference between the 2 
electrodes (field intensity) and the frequency: at very low fre-
quencies (<1 kHz) excitable cells such as neurons or myocytes 
will be depolarized.1 Cardiac pacemakers or deep brain stimu-
lators work in this range of frequency. At very high frequencies 
(>MHz), heat is generated in the tissues due to dielectric loss. 
This property is mainly used for radiofrequency ablation or 
diathermy treatments.2 The alternating frequency of electrical 
fields at intermediate frequencies (range, 10–1000 kHz) is too 
fast to induce cell depolarization and induces no or only mini-
mal heat by dielectric loss. In the past, these frequencies were 
considered to have no interaction with biological processes.3 
Nevertheless, a number of effects have been observed in bio-
logical tissues such as microscopic particle alignment,4 cell 
rotation,5 and transient pore formation in cell membranes.6 
At low intensities (2V/cm) and intermediate alternating fre-
quencies (between 100–300 kHz), Kirson and Palti et al. dem-
onstrated a specific inhibiting effect on cell division in cancer 
cell culture models.7
Tumor treating fields (TTFields) are alternating, low-intensity, 
intermediate frequency electric fields that aim to disrupt cell 
division and inhibit tumor growth. In initial experiments, expo-
sure of a variety of tumor cell lines to TTFields was shown to 
exert a profound growth inhibitory effect by inducing cell cycle 
arrest and apoptosis, while no effect was induced on non-divid-
ing cells.7 These in vitro observations could also be confirmed in 
vivo in mice and rabbit tumor models.8 Further studies demon-
strated that the growth inhibitory effect is largely mediated by 
interference on the mitotic spindle apparatus. TTFields will target 
proteins with large dipole moments (ie, septins and the spin-
dle microtubules, components essential in the metaphase and 
anaphase stages of the mitotic cycle for separation and equal 
distribution of chromosomes).9,10 Furthermore, inhibition of the 
polymerization of microtubules interferes with proper assembly 
of the mitotic spindle apparatus. In telophase, during cytokinesis 
the hourglass shape taken by the daughter cells that are about 
to separate induces a nonuniform electric field that is strongly 
enhanced at the level of the furrow region (→ fig. 1). This results 
in dielectrophoretic forces that may attract charged molecules 
from the cytosol and compromise normal cytokinesis.7 The 
antitumoral effect results from disruption of the microtubular 
assembly during mitosis, blocking formation of the mitotic spin-
dle apparatus and blocking separation of the 2 daughter cells.9 
This effect also results in abnormal chromosomal segregation 
and reduced clonogenic potential of the cell’s progeny.10
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Animal models of various tumors, including glioblas-
toma (GBM), non–small cell lung cancer, pancreatic can-
cer, and malignant melanoma confirmed the inhibition of 
tumor growth or metastatic seeding when externally applied 
TTFields were delivered at the appropriate frequencies.11 As 
an example, an experimental model of rats with intracrani-
ally inoculated GBM cells treated with TTFields at a frequency 
of 200 kHz over 6 days showed smaller tumors compared 
with untreated rats.12 The inhibitory effect was significantly 
increased when 2 or more, rather than 1 field directions were 
used.12 Importantly, synergistic antitumor activity was dem-
onstrated when TTFields were applied in conjunction with 
cytotoxic chemotherapy with paclitaxel, doxorubicin, cyclo-
phosphamide, or dacarbazine (DTIC).13
In summary, TTFields will block the mitotic cell cycle, in 
particular during metaphase, anaphase, and telophase. This 
will result in cell cycle arrest or delay in cell division and inter-
fere with organelle assembly, particularly the spindle appara-
tus (fig. 1 C). The consequences are inadequate cell division 
and unequal chromosome distribution. Ultimately, cells 
will die in apoptosis. In order to have an optimal treatment 
effect, the field intensity and frequency needs to be adapted 
to the tumor type and cell properties (eg, cell size). The opti-
mal frequency to maximize the antitumor effect is inversely 
correlated with cell size and when the incident angle of the 
electrical field is perpendicular to the mitotic plate.7
As the cell division may occur at any time, prolonged expo-
sure to the electrical fields is required for maximal effect. For 
the delivery of TTFields, a portable and battery-powered device 
has been developed (→ fig. 2). The electric field is applied to 
the brain through 4 transducer arrays with 9 insulated elec-
trodes each and continuous temperature sensing fixed to the 
patient’s shaved scalp.
Clinical Experience:
Glioblastoma as a Proof of Concept Model
In the very first clinical application, TTFields treatment was 
applied to patients with cutaneous metastases of melanoma 
or breast cancer. Tumor shrinkage or even complete disappear-
ance was demonstrated.12,14 However, metastatic cancer is a 
systemic disease, thus most effects of application of TTFields 
would be expected to be seen in diseases or situations where 
primarily locoregional control is warranted. Primary brain 
tumors—and notably glioma—rarely metastasize; recurrence 
in the brain is the predominant cause of treatment failure and 
was chosen as the first disease in which the effect of TTFields 
could be investigated prospectively.
Fig. 1. Mechanisms of action of tumor treating fields in and around quiescent and dividing cells. Inside quiescent cells (1A), the field is uniform, 
and the oscillating electric forces result only in ‘‘vibration’’ of ions and dipoles (the forces associated with each half cycle are denoted with white 
and gray arrows). In contrast, the nonuniform field within dividing cells (1B) induces forces pushing all dipoles toward the furrow. [reprinted with 
permission from ref. 12] 1C: Tumor treating fields (TTFields) exert directional forces and result in abnormal spindle formation and subsequent 
mitotic arrest or delay, possibly due to improper attachment of chromosomes to the spindle fibers. Cells can die in mitotic arrest or progress 
to cell division leading to abnormal aneuploid progeny (highlighted by bold arrow). Abnormal daughter cells die in the subsequent interphase, 
undergo a permanent arrest or proliferate through additional mitosis where they will be subjected to further TTFields assault. [adapted with 
permission, refs. 11 and 12]
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In a computational model, the optimal frequency of 
TTFields for GBM was found to be in the range of 200 kHz. 
The field strength should be ≥ 1 V/cm. These TTFields are 
able to penetrate into the deep brain tissue from the sur-
face of the scalp. The computational model also revealed 
inhomogeneous fields with intensification of the field 
strength near the ventricles as a result of the high con-
ductivity of the cerebrospinal fluid. Necrotic areas and 
edematous regions also showed high conductivity of the 
TTFields. In contrast, areas with high cellularity showed 
lower conductivity.15
Following the demonstration of feasibility in a small pilot 
trial, the clinical merits of this innovative cancer treatment 
were evaluated in 2 pivotal randomized trials in recurrent (EF-
11) and newly diagnosed (EF-14) GBM. In our summary, herein 
we always refer to the results of the intent-to-treat population 
(ITT); for details on the predefined per protocol populations, 
the reader is kindly directed to the respective original publica-
tions16,17 (→ table 1).
TTFields in Recurrent Glioblastoma
The EF-11 Trial
For this trial, GBM patients with progressive or recurrent dis-
ease after initial treatment with radiotherapy and TMZ chemo-
therapy were eligible. Patients may have received several lines 
of prior chemotherapy. A total of 237 patients were then rand-
omized 1:1 to either the novel TTFields therapy (120 patients) 
or to the best available treatment (117 patients) according to 
the local oncologist’s best choice (active control, fig. 3A). The 
primary endpoint of the trial was OS. Patients’ median age 
was 54 years, with a median KPS of 80% (range, 50–100%). 
Eighty-eight percent of patients had received 2 or more lines 
of prior chemotherapy including prior bevacizumab in 18% of 
patients. With a median survival of only 6.6 and 6.0 months 
in the TTFields and the control arm, respectively (hazard ratio: 
0.86 [95% CI, 0.66–1.12), P=0.27) and a 1-year survival rate of 
only 20% in both groups, the trial failed to demonstrate supe-
riority over “established” or commonly used chemotherapy 
Fig. 2. Tumor treating fields (TTFields) device (2nd generation Optune) and its clinical use TTFields are administered by 4 transducer arrays placed 
on the shaved scalp and connected to a portable device generating 200 kHz electric fields within the brain. The position of the transducer arrays 
are determined by the localization of the tumor using a mapping software (NovoTalTM). (Photo with permission from the patient)
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regimens. The median duration of TTFields administration 
was only 2.3 months (95% CI, 2.1– 2.4) with tumor progres-
sion as the primary reason for discontinuation of treatment. 
Still it showed objective responses with TTFields alone in 14% 
of patients compared with 9.6% in the control arm. The study 
demonstrated safety and feasibility of TTFields in a large mul-
ticenter setting.
The design and conduct of the EF-11 trial had some inher-
ent limitations: numerous prior treatment lines were allowed 
and led to a heterogeneous patient population. More than 
40% of patients were included after the third recurrence, 
including many patients who had failed prior bevacizumab 
therapy. Thus, most patients suffered from very advanced dis-
ease and had only few available treatment options and lim-
ited life expectancy. In the absence of a commonly accepted 
standard treatment for recurrent GBM, the control patients 
were to receive the best available systemic therapy according 
to the current local practice. The heterogeneity of treatments 
prescribed to the control patients reflects this fact: about one-
third of the control patients received bevacizumab alone or 
in combination, 25% nitrosoureas, and 11% re-exposure to 
TMZ. A number of patients were discontinued from TTFields 
therapy very early (after <1 month of therapy), presumably 
due to absence of a treatment response (rather than true 
tumor progression) based on skepticism of the investigators. 
It is known that TTFields take a prolonged period of time until 
its effects can be clinically demonstrated or that delayed 
responses may occur after initial radiological tumor growth; 
thus, some patients may have discontinued TTFields treat-
ment prematurely.
Based on the results of the EF-11 trial, the US Food and Drug 
Administration (FDA) felt that these results provided reasonable 
Table 1. Results of EF-14 & EF-11 trials
Trial Treatment arm Number of 
patients
Progression-free survival Overall survival
Median at 6 months Median at 1 year at 2 years
EF-14: newly 
diagnosed [Interim 
data set]
TTFields & TMZ  210 (466 total) 7.1 mo* 57% 19.6 mo 75% 43% (36–50)
Maintenance TMZ  105 (229 total) 4.0 mo* 34% 16.6 mo 69% 29% (21–39)
Hazard ratio 0.63 (CI, 0.43–0.89) 0.74 (CI, 0.56–0.98)
P value < 0.01 (stat. significant) 0.0004 (stat significant)
EF-11: recurrent GBM TTFields 120 2.2 mo. 21% 6.6 mo* 20% 8%
chemotherapy¶ 117 2.1 mo. 15% 6.0 mo* 20% 4%
Hazard ratio 0.81 (CI,0.60–1.09) 0.86 (0.66–1.22)
P value 0.13 (not significant) 0.27 (not significant)
Abbreviations: CI, 95% confidence interval; mo, months; TMZ, temozolomide; TTFields, Tumor Treating Fields; EF, electrical fields
¶: best physician’s choice chemotherapy as active control
*: primary trial endpoint, other values are predefined secondary endpoints
Fig. 3. Design of the pivotal trials in GBM. A: EF-11 Trial Design B: EF-14 Trial Design
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assurance that the benefits of TTFields outweigh its risks when 
administered as monotherapy in place of standard medi-
cal therapy and therefore approved TTFields in 2011 (http://
www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm251669.htm).
TTFields in Daily Practice: PriDE Dataset
After FDA approval, TTFields became commercially available 
in the United States, and Mrugala et al summarized the daily 
practice experience on 457 patients treated at 91 US institu-
tions (Patient Registry Dataset; PRiDe).18 Interestingly, patients’ 
age and performance status were similar in this dataset and in 
the EF-11 trial; however, treatment with TTFields was initiated 
much earlier in the course of the disease. One-third of patients 
were treated at first recurrence (compared with 9% in the EF11 
trial). Overall, median survival was 9.6 months, and the sub-
group of patients who were treated at first recurrence (n=152) 
had a median survival of 20 months.18
TTFields in Newly Diagnosed GBM (EF-14 Trial)
This open label phase 3 study in patients with newly diagnosed 
GBM was initiated while the trial for recurrent disease was still 
ongoing. For practical reasons (interference of the electrodes 
during radiotherapy), patients had to be randomized only after 
completion of standard concomitant TMZ chemoradiotherapy 
to standard maintenance TMZ chemotherapy (for 6–12 cycles) 
with or without concomitant administration of TTFields (fig. 3B). 
The primary endpoint was PFS, and OS was a powered second-
ary endpoint. Eligible adult patients (KPS ≥  70%, supratento-
rial tumor location) had to be progression-free after the end of 
chemoradiotherapy, thus excluding the patients with the worst 
prognosis. After stratification by extent of resection (biopsy, par-
tial resection, gross total resection, determined on MRI 24–48 
hours postsurgery) and MGMT status (methylated, unmethyl-
ated, unknown) patients were randomized at a ratio of 2:1 within 
3–7 weeks from the last day of radiation. Patients assigned for 
TTFields therapy received additional instruction and technical 
support for the use of the device by a device specialist (tech-
nician) during the first weeks of treatment and thereafter with 
monthly visits. This support was limited to technical aspects of 
the device and assistance with the application of arrays.
A total of 695 patients from 83 centers across the world were 
included between July 2009 and November 2014. More than half 
of the patients came from the United States. The medical follow-
up was similar in both treatment arms. It included monthly clinic 
visits for complete physical examination and blood hematol-
ogy and chemistry analyses. A mini-mental status examination 
(MMSE), quality of life evaluation (EORTC QLQ-C30 questionnaire 
and the brain-specific module BN-20) were performed at base-
line and every 3 months thereafter.19,20 MRI and disease assess-
ment using the Macdonald criteria were to be performed every 
2 months. All treatment-related clinical decisions were based on 
local interpretation of imaging; however, a blinded central imag-
ing and disease assessment review determined the date of pro-
gression. Patients experiencing tumor progression were offered 
second-line treatment according to local practices. Patients were 
allowed to continue TTFields treatment beyond first progression 
based on the prior experience of pseudoprogression and delayed 
responses. For the purpose of the trial, the date of first progres-
sion, as assessed by the independent review panel, was consid-
ered the primary endpoint.
The baseline patient characteristics were well balanced 
between the 2 groups. In both groups, 66% were male, and 
the median age at inclusion was 57 years (range, 20–83y), 
and the median KPS was 90%. Sixty-four percent of patients 
underwent gross total resection, and 11% had biopsy only. 
Central MGMT gene promoter methylation analysis was avail-
able for 72% of patients. MGMT was methylated in 39% of 
patients in the TTFields/TMZ group and in 41% of the control 
TMZ group. The median time from end of radiation therapy to 
randomization was 36 and 38 days in the TTFields and control 
groups, respectively. The median time from randomization to 
initiation of TTFields was 5 days. Median time from diagno-
sis of GBM to randomization was 3.8 months in both groups 
(ranges, 2.0–5.7 and 1.4–5.7 months in the treatment and 
control groups, respectively). Of note, 53% of patients were 
randomized after initiation of the first cycle of TMZ (as allowed 
by the protocol). Per protocol, TTFields treatment was contin-
ued up to the second progression in two-thirds of the patients; 
the median duration of treatment with TTFields was 9 months 
(range, 1–58 mo). Three-quarters of patients receiving treat-
ment with TTFields were adherent to therapy as prescribed (ie, 
wearing the device ≥ 18 hours per day on average during the 
first 3 treatment months) (n=157/210).
At a prespecified interim and futility analysis to be per-
formed once the first 315 randomized patients reached a 
minimum follow-up of 18 months, a significant improvement 
in progression-free and overall survival was seen; conse-
quently the independent data monitoring committee recom-
mended that the trial be terminated early for success and 
that patients be allowed to cross over to the TTFields arm. 
In the interim analysis, the ITT median PFS was increased by 
3.1 months in the TTFields group with a median PFS of 7.1 
months (95% CI, 5.9–8.2 mo) compared with 4.0 months 
(95% CI, 3.3–5.2 mo) in the control group (HR, 0.62 [98.7% 
CI, 0.43–0.89]; P=.001). As a direct consequence, patients 
in the control group received a median of 4 cycles of TMZ 
(range, 1–24), whereas patients in the TTFields group received 
a median of 6 cycles (range,1–26) of TMZ. Median OS from 
randomization (ITT) was 19.6 months (95% CI, 16.6–24.4 mo) 
in the TTFields plus TMZ group compared with 16.6 months 
(95% CI, 13.6–19.2 mo) in the TMZ control group (HR: 0.74 
[95% CI, 0.56–0.98]; P =.03). The percentage of patients alive 
at 2 years following enrollment was 43% in the TTFields/TMZ 
group and 29% in the TMZ alone group (P=.006)17 (→ fig. 4). 
At first progression, 67% of the patients in the TTFields/TMZ 
group received a second-line therapy compared with 57% of 
patients in the TMZ control group. The type of salvage chemo-
therapy offered was balanced between the 2 groups: about 
40% of second-line therapies included bevacizumab and 
about 40% nitrosoureas.
Preliminary subgroup analyses showed that the positive 
effect observed on PFS and OS by the addition of TTFields 
was not restricted to any subgroup of patients: in particular 
neither age, performance status, MGMT methylation status 
nor extent of resection was predictive for a better treatment 
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effect. However, the sample size of the interim dataset may 
not be large enough to identify meaningful subgroups, and 
detailed subgroup analyses are to be performed on the final 
and validated dataset. Due to the 2:1 randomization, the con-
trol arm comprised only 105 patients, which limited the ability 
to perform formal subgroup analyses. In the final dataset, the 
control group will comprise 229 patients. Before publication 
of the interim analysis, the overall dataset of 695 randomized 
patients was statistically scrutinized. It was concluded that 
the results are unlikely to change substantially once the whole 
dataset reaches a mature follow-up (see supplemental mate-
rial, reference17). In October 2015, the FDA approved TTFields 
for use in newly diagnosed GBM patients.
Toxicity, Support, and Quality of Life with TTFields
Toxicity related to TTFields therapy consisted, by the nature 
of this treatment, mainly of local skin irritation. This is usually 
mild, self-limiting, easily manageable with local application of 
steroid-containing ointments, and may require an occasional 
treatment break for a few days. In the EF-11 trial, skin toxic-
ity was reported in 16% of patients (grade 3 in only 2%). In 
the EF-14 trial for newly diagnosed GBM patients, where the 
treatment exposure was longer than that for recurrent disease, 
grades 1 and 2 skin reactions were reported in 43% of patients. 
Severe (grade 3)  reactions were again seen in only 2% of 
patients. Examples of allergic contact dermatitis, irritant con-
tact dermatitis, folliculitis, and erosions are shown in → fig. 5.21
Importantly, when compared with TMZ maintenance 
treatment alone, the addition of TTFields did not result in 
any modification of the overall incidence, severity, and dis-
tribution of side effects in patients with newly diagnosed 
GBM. The incidence of seizures was identical in both treat-
ment groups (7% in the TTFields group vs 8% in the control 
group). Some nonspecific adverse effects including nerv-
ous system disorders such as grade 1–2 headache (21% 
in the experimental group vs 14% in patients with TMZ 
alone), mild anxiety, confusion, insomnia, and headaches 
were reported more frequently in the patients treated with 
TTFields plus TMZ and occurred mainly at the time of ther-
apy initiation.
Given the need for continuous and long-term use of the 
TTFields device, the quality of life of patients has been a con-
cern. In the EF-11 trial, there were no differences in global 
health and social functioning between patients treated with 
TTFields or chemotherapy. In fact, cognitive and emotional 
functioning was higher in the TTFields group than in the chem-
otherapy group.16 In the EF-14 trial, preliminary quality of life 
Fig. 4. Progression-free and overall survival in EF-11 (A&B) & EF-14 (C&D) trials. EF-11 trial: Progression-free survival (A) and overall survival (B) of 
the intent-to-treat population. Hazard ratio for overall survival: 0.86 (CI, 0.66–1.12, P=0.66) [Reprinted with permission from ref, 16] Progression-
free survival (C) and overall survival (D) of the intent-to-treat population in the EF-14 trial (interim data set). Hazard ratio for progression 0.63 
(95%CI 0.43–0.89, P<0.01); for survival 0.74 (CI 0.56–0.98, P=0.0004). [Reprinted with permission, ref. 17]
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data showed identical scores at baseline and at 12 months 
for patients in the treatment and control groups at the lev-
els of cognitive, emotional, physical, and social functioning.22 
Moreover, the global health status showed an improvement 
at 3 and 6 months in comparison with baseline for patients 
treated with TTFields and TMZ, whereas patients in the con-
trol group showed a decrease in global health status over the 
same time period.
Discussion
More than a decade ago, in vitro and in vivo experiments in 
tumor cell lines and in mouse, rat, and rabbit tumor models 
have demonstrated antitumor activity of low-intensity, inter-
mediate-frequency alternating electric fields. Dividing cells 
are arrested in metaphase and anaphase, assembly and func-
tion of the mitotic spindle are perturbed, and cells ultimately 
undergo apoptosis. However, in order to translate these find-
ings into a clinically useful treatment, certain conditions must 
be met: (1) TTFields need to be delivered in a continuous 
manner to achieve the expected cytotoxic effect; (2) TTFields 
can only be applied to certain areas of the body, and this (3) 
requires the possibility to affix transducer array to the skin of 
the patient over the area of the tumor. As GBM is a disease that 
remains confined to the CNS and the scalp offers an easy appli-
cation site for long-term use of transducer arrays, it appeared 
to be the ideal candidate to serve as a proof of concept dem-
onstration of TTFields.
Two pivotal randomized trials have been reported to 
date. In recurrent disease, the trial has not demonstrated 
improved outcome compared best physicians’ choice chem-
otherapy. However, TTFields when administered as part of 
the initial treatment in newly diagnosed patients showed a 
consistent prolongation of both PFS and OS (hazard ratio for 
death HR: 0.74 (95% CI, 0.56–0.98). Giving TTFields early in 
the disease course allows for prolonged exposure, and the 
in vitro observed synergy with TMZ may further enhance its 
efficacy. The median treatment duration in recurrent dis-
ease was only 2.3 months compared with 9 months in newly 
diagnosed GBM. Still, TTFields alone in recurrent disease have 
shown objective responses in 14% of patients, consistent or 
even numerically higher than that observed in other trials 
using alkylating agent chemotherapy with lomustine 23,24 or 
TMZ.25 In the PriDE dataset reflecting routine clinical use of 
the device, patients who received TTFields at first recurrence 
were treated for a median of 6.2 months and had a median 
survival of 20 months, comparing favorably with recent trial 
results investigating other novel agents. However, a strong 
selection bias and inclusion of patients with pseudoprogres-
sion after initial TMZ chemoradiotherapy cannot be ruled out 
in this uncontrolled routine practice patient population.26 The 
best results with this novel treatment modality have been 
achieved when TTFields were administered early in the dis-
ease course in combination with standard maintenance TMZ 
therapy,17 similar to that shown 10 years ago when TMZ was 
added to standard radiotherapy.
It may be scientifically regrettable that the trial had to be 
open label and did not include a double-blinded control group. 
However, a sham device would neither be practically feasi-
ble (some heating of the electrodes is inevitable; technically 
Fig. 5. Skin toxicities observed under tumor treating fields (TTFields). Some mild-moderate (grade 1–2) skin reaction is observed in up to half of 
patients (in EF-14 trial reported in 43%, grade 3 in 2%); however, it is usually self-limiting and resolves by removing the electrodes for a few days 
and applying local steroid-containing ointments. The images represent a few examples of skin reactions. (A) allergic contact dermatitis (B) irritant 
contact dermatitis (C) folliculitis (D), erosions [Reproduced from ref. 21].
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savvy patients would rapidly figure out whether there is any 
current flowing), nor acceptable for patients, caregivers, and 
ethics committees given the perceived burden of shaving the 
scalp and replacing transducer arrays every 3 days. Whereas 
some placebo effect might be expected on subjective end-
points, such as quality of life or cognitive function, it is difficult 
to envision an effect on objective endpoints such as OS or PFS 
(especially when progression was determined by blinded cen-
tral radiologists).27 Requiring a placebo or sham device would 
also mean a paradigm shift in conducting clinical trials with 
survival endpoints in oncology. Sham radiation therapy would 
be required for RT trials, and a placebo control would only be 
feasible for agents that have rare and mild toxicities.
Indeed, patients receiving TTField therapy received some 
additional assistance by the technical support team providing 
the TTFields device and arrays. However, this support was on 
average limited to 1 visit per month, and 1–2 extra visits or 
contacts at the initiation of treatment. Most patients became 
rapidly independent and self-proficient with the device; on 
average, there was a median of 1.12 visits per patient and 
month of treatment (range, 0.5–4 visits per month).
It is highly unlikely that this additional technical support 
would translate into a 3-month prolongation of median sur-
vival, which is in the range of the benefit seen with the intro-
duction of TMZ.26 In a contemporary randomized open-label 
non-placebo-controlled trial, patients in the experimental arm 
received twice weekly i.v. administration of cilengitide. Still, 
this did not translate into any benefit in outcome (hazard ratio 
for death: 1·02; 95% CI 0·81–1·29).28
It might have been possible that the control arm in EF-14 
performed exceptionally poorly. We thus scrutinized the 
data and compared the performance of the control arms of 
contemporary trials. The patient characteristics of both the 
TTFields and control groups were comparable with other clini-
cal trials for newly diagnosed GBM patients in respect to all 
known prognostic factors (distribution of age, performance 
status, extent of resection, MGMT status).
One important difference in the EF-14 trial compared with 
many other reports is that patients were randomized only 
after the end of chemoradiotherapy, and for most patients 
the first cycle of maintenance TMZ had already been started 
at time of randomization. This implies that all patients with 
early tumor progression during the concomitant radiation 
and TMZ part of the treatment were excluded from this 
trial. On the other hand, the 3.8 months from diagnosis to 
randomization will need to be added to survival times in 
order to have an estimate of the individual patients’ effec-
tive outcome. The PFS of 4.0 months (from randomization) 
observed in the control group of the EF14 trial is numeri-
cally shorter (likely due to the independent imaging review 
and assessment of progression) but overall comparable to 
the observed PFS of 5.5 months observed in the RTOG 0525 
trial,29 a trial that also randomized patients only after com-
pletion of the concomitant radiochemotherapy part of treat-
ment. Moreover, in both trials, the OS was identical at 16.6 
months for the control groups. It is therefore unlikely that 
the benefit observed in the treatment group of the EF14 trial 
can be attributed to patient selection and a poor outcome of 
patients in the control arm.
For many experts in neuro-oncology who were not involved 
in the trial, the most important criticism to TTFields was the 
requirement for patients to wear a device and their presumed 
stigmatization. Having to shave the scalp is indeed a psycho-
logical barrier, although in oncology, for decades we have 
been using cytotoxic agents that are inducing complete hair 
loss of all body hair and not only the scalp. In our experience, 
patients and families rapidly adapt to wearing the device and 
are able to continue their regular activities including work and 
even sports. Preliminary analysis of the self-reported quality of 
life data from the EF14 trial showed identical scores for both 
groups at baseline and at 12 months for patients in the treat-
ment and control group at the levels of cognitive, emotional, 
physical, and social functioning.22 To reduce some of the bur-
den of therapy, a second generation of the TTFields device 
with a reduction in size and weight by about 50% compared 
with the device used in the EF-11 and EF-14 devices has been 
developed.
Conclusions & Future Perspectives
The results of the randomized phase III EF-14 trial provide 
level 1 evidence that alternating electric fields are able to posi-
tively impact tumor growth and significantly extend survival in 
GBM. As a logical consequence, TTFields were approved by the 
FDA for newly diagnosed GBM in October 2015. Nevertheless, 
numerous questions remain and need to be addressed, both 
within the EF-14 trial and in future studies; Notably, it will be 
essential to be able to (1) identify the patients most likely to 
respond to TTFields therapy, (2) further elucidate the mecha-
nism of action of TTFields, (3) elucidate the mechanisms of 
resistance to and failure of TTFields therapy, and (4) elucidate 
the pattern and predictors of response.
In GBM we will need to integrate this novel treatment 
approach in the current standard of care, and ultimately novel 
clinical trials will also need to integrate TTFields (at least in the 
control arm). A pragmatic alternative is to stratify patients for 
the use of TTFields as part of their standard of care in both the 
standard and experimental arms.
TTFields is a locoregional treatment, and extending its use 
to other tumor types and metastatic disease is most promising 
in clinical situations where locoregional disease control is key 
for quality of life. The excellent compatibility between TTFields 
and various chemotherapeutic agents has already been dem-
onstrated, not only in GBM patients in the EF-14 trial but also 
in lung cancer patients.30 TTFields may also be synergistic with 
immune therapy approaches. Senovilla et al showed that cells 
that cannot undergo mitotic exit show hallmarks of immuno-
genic cell death where the immune system induces a strong 
response against the dying cells.31
The positive results of the EF-14 demonstrate that neuro-
oncology can lead the way to innovation. The results of the 
EF-14 trial paves the way to investigate the role of alternat-
ing electrical fields in other oncologic situations amenable 
to locoregional treatment such as brain metastases, ovarian 
carcinoma, mesothelioma, or pancreatic tumors (→ table 2). 
These trials are currently ongoing. For instance, in pancreatic 
cancer, TTfields therapy, in addition to gemcitabine resulted in 
a median PFS of 8.3 months (CI, 3–10.3 mo) in a phase 2 study 
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on 20 patients. The partial response rate was 30% and another 
30% stable disease. The median OS for all patients was prom-
ising for this disease at 14.9 months. It was not reached in 
patients with locally advanced disease, and 8.3 months (CI, 
4.3–14.9 mo) for patients with metastatic disease with 1-year 
survival rates of 86% in locally advanced patients and 40% in 
patients with metastatic disease32 If those trials confirm the 
positive effects observed in GBM patients, a truly new cancer 
treatment modality has been born and will find multiple useful 
indications alone or in combination with other established or 
new treatments.
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